España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Arbutus Biopharma
ABUS
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$3.22
0.01
0.31%
At close: -
$3.22
0.00
0.00%
After Hours: 4:00 PM EDT
Get Report
Comment
Arbutus Biopharma (ABUS) Forecast
News
Earnings
Arbutus Biopharma (ABUS) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Arbutus Biopharma (NASDAQ:ABUS) Stock
Arbutus Biopharma Stock (NASDAQ: ABUS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, January 21, 2025
HC Wainwright & Co. Reiterates Buy on Arbutus...
Benzinga Newsdesk
Monday, January 13, 2025
Arbutus Biopharma Held $123M In Cash Balance,...
Benzinga Newsdesk
Tuesday, December 03, 2024
Whitefort Capital Sends Letter To Arbutus Bio...
Benzinga Newsdesk
Wednesday, November 20, 2024
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor
Chardan Capital Maintains Buy on Arbutus Biop...
Benzinga Newsdesk
Monday, November 18, 2024
HC Wainwright & Co. Reiterates Buy on Arbutus...
Benzinga Newsdesk
Friday, November 15, 2024
Barinthus Biotherapeutics shares are trading ...
Benzinga Newsdesk
Arbutus And Barinthus Bio Report IM-PROVE II ...
Benzinga Newsdesk
Thursday, November 07, 2024
HC Wainwright & Co. Reiterates Buy on Arbutus...
Benzinga Newsdesk
Chardan Capital Maintains Buy on Arbutus Biop...
Benzinga Newsdesk
Wednesday, November 06, 2024
As Of September 30, 2024, Arbutus Had Cash, C...
Benzinga Newsdesk
Arbutus Biopharma Q3 2024 GAAP EPS $(0.10) Mi...
Benzinga Newsdesk
Tuesday, October 15, 2024
Arbutus Announces Multiple Abstracts Highligh...
Benzinga Newsdesk
Thursday, October 03, 2024
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Vandana Singh
Thursday, September 05, 2024
Jefferies Maintains Buy on Arbutus Biopharma,...
Benzinga Newsdesk
Friday, August 02, 2024
JMP Securities Maintains Market Outperform on...
Benzinga Newsdesk
Thursday, August 01, 2024
Trading Halt: Halt status updated at 7:55:00 ...
Benzinga Newsdesk
Arbutus Will Cease Discovery Efforts And Disc...
Benzinga Newsdesk
Arbutus Biopharma Q2 2024 GAAP EPS $(0.11) Mi...
Benzinga Newsdesk
Trading Halt: Halted at 7:25:00 a.m. ET - Tra...
Benzinga Newsdesk
Friday, June 07, 2024
HC Wainwright & Co. Reiterates Buy on Arbutus...
Benzinga Newsdesk
Thursday, June 06, 2024
Barinthus Biotherapeutics Presents Updated Da...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Arbutus...
Benzinga Newsdesk
Wednesday, June 05, 2024
Chardan Capital Maintains Buy on Arbutus Biop...
Benzinga Newsdesk
Arbutus's Imdusiran Combined With Short-Term ...
Benzinga Newsdesk
Wednesday, May 22, 2024
Arbutus Biopharma Announces Presentation Of I...
Benzinga Newsdesk
Monday, May 20, 2024
Genevant Sciences And Arbutus Biopharma Win D...
Benzinga Newsdesk
Friday, May 03, 2024
Chardan Capital Reiterates Buy on Arbutus Bio...
Benzinga Newsdesk
Thursday, May 02, 2024
Arbutus Biopharma Q1 EPS $(0.10) Beats $(0.11...
Benzinga Newsdesk
Thursday, April 04, 2024
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
Vandana Singh
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
Surbhi Jain
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Arbutus Biopharma Announces Claim Constructio...
Benzinga Newsdesk
Wednesday, April 03, 2024
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
Neil Dennis
Arbutus Biopharma shares are trading higher a...
Benzinga Newsdesk
Watching Arbutus Biopharma; Traders Circulate...
Benzinga Newsdesk
Friday, March 01, 2024
Chardan Capital Reiterates Buy on Arbutus Bio...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Arbutus ...
Benzinga Newsdesk
Thursday, February 29, 2024
Arbutus Biopharma's 2023 End Cash And Investm...
Benzinga Newsdesk
Arbutus Biopharma Q4 EPS $(0.12), Inline, Sal...
Benzinga Newsdesk
Earnings Scheduled For February 29, 2024
Benzinga Insights
Thursday, February 08, 2024
Watching Arbutus Biopharma; Hearing Jefferies...
Benzinga Newsdesk
Thursday, November 09, 2023
Barinthus Bio Said Initial Data From The Combination Of Imdusiran And VTP-300 Show Meaningful Reductions Of HBsAg Levels That Were Maintained Well Below Baseline.
Charles Gross
Tuesday, November 07, 2023
Arbutus Biopharma Q3 2023 EPS $(0.12) Misses ...
Benzinga Newsdesk
Arbutus Says Announces Workforce Reduction Of...
Benzinga Newsdesk
Arbutus CEO William Collier To Retire At The ...
Benzinga Newsdesk
Arbutus CEO William Collier To Retire Dec. 31...
Benzinga Newsdesk
Earnings Scheduled For November 7, 2023
Benzinga Insights
Thursday, October 05, 2023
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
Vandana Singh
Tuesday, September 12, 2023
HC Wainwright & Co. Reiterates Buy on Arbutus...
Benzinga Newsdesk
Show More
